{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    8,
    9,
    20,
    41,
    44,
    56,
    57
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Statistical Testing Update",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9",
        "sectionTitle": "Statistical Considerations",
        "description": "Revision of secondary efficacy endpoint analysis to allow formal statistical testing."
      },
      {
        "id": "ref_2",
        "name": "Sample Size Determination",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2",
        "sectionTitle": "Sample Size Determination",
        "description": "Update to align with the statistical analytical plan (SAP)."
      },
      {
        "id": "ref_3",
        "name": "Treatment Satisfaction Questionnaire",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.14.11",
        "sectionTitle": "Treatment Satisfaction Questionnaire for Medication",
        "description": "Appendix updated to include a copy of the full questionnaire."
      },
      {
        "id": "ref_4",
        "name": "Exit Interview Description",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.3",
        "sectionTitle": "Exit interviews",
        "description": "New section providing a description of the assessment."
      },
      {
        "id": "ref_5",
        "name": "Inhibitor Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.1.1",
        "sectionTitle": "Inhibitor development",
        "description": "Reference for the definition of inhibitor development in relation to stopping rules."
      },
      {
        "id": "ref_6",
        "name": "Regulatory Oversight",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.1",
        "sectionTitle": "Appendix 1: Regulatory, Ethical, and Study Oversight Considerations",
        "description": "Reference for informed consent process requirements."
      },
      {
        "id": "ref_7",
        "name": "Italy Specific Requirements",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.11.2",
        "sectionTitle": "Italy",
        "description": "Reference for specific renal function exclusion criteria for Italy."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Interviews will be conducted with a subset of participants and may be done up to 6 months after the Week 52/EOS Visit, but before the EOS is declared.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 21
      },
      {
        "id": "annot_2",
        "text": "ePD training only. ePD devices are given to the patients at the baseline visit",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "In the case of minor dental surgery, blood samples can be drawn within 3 days prior to the day of surgery.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 3
      },
      {
        "id": "annot_4",
        "text": "Any and all information presented in this document shall be treated as confidential and shall remain the exclusive property of Sanofi.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Cover Page",
        "pageNumber": 1
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1 (electronic 7.0)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-20",
        "description": "Amended Clinical Trial Protocol 05 incorporating addition of statistical testing and exit interviews.",
        "amendmentNumber": "5"
      },
      {
        "id": "ver_2",
        "versionNumber": "1 (electronic 5.0)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-13",
        "description": "Amended Clinical Trial Protocol 04",
        "amendmentNumber": "4"
      },
      {
        "id": "ver_3",
        "versionNumber": "1 (electronic 4.0)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-04-06",
        "description": "Amended Clinical Trial Protocol 03 (Italy only)",
        "amendmentNumber": "3"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}